.gif)
Patients with advanced melanoma skin cancer survive for longer without their disease progressing if they have been treated with a combination of two drugs, nivolumab and ipilimumab, than with either of these drugs alone. New results show that these patients also do better regardless of their age, stage of disease and whether or not they have a cancer-driving mutation in the BRAF gene.
European Commission (EC) has granted marketing authorization for Praluent® (alirocumab) for the treatment of bad cholesterol, known as low-density lipoprotein (LDL) cholesterol, in certain adult patients with hypercholesterolemia. Praluent is the only EC-approved PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor that is available in two starting doses as a single 1-milliter (mL) injection (75 mg and 150 mg) once every two weeks, offering two levels of efficacy. Praluent will be available in a single-dose pre-filled pen that patients self-administer.
Self-assembled DNA nanostructures can be used in molecular-scale diagnostics and as smart drug-delivery vehicles.
Researchers from Aalto University have published an article in the recent Trends in Biotechnology journal. The article discusses how DNA molecules can be assembled into tailored and complex nanostructures, and further, how these structures can find uses in therapeutics and bionanotechnological applications. In the review article, the researchers outline the superior properties of DNA nanostructures, and how these features enable the development of efficient biological DNA-nanomachines. Moreover, these DNA nanostructures provide new applications in molecular medicine, such as novel approaches in tackling cancer. Tailored DNA structures could find targeted cells and release their molecular payload (drugs or antibodies) selectively into these cells.
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
Also Join: 
.png)
